K Mujoo
Overview
Explore the profile of K Mujoo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
552
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang Z, Choi B, Mujoo K, Fan X, Fa M, Mukherjee S, et al.
Oncogene
. 2014 Mar;
34(9):1105-15.
PMID: 24662824
HER3/ErbB3, a member of the epidermal growth factor receptor (EGFR) family, has a pivotal role in cancer and is emerging as a therapeutic antibody target. In this study, we identified...
2.
Mujoo K, Haridas V, Hoffmann J, Wachter G, Hutter L, Lu Y, et al.
Cancer Res
. 2001 Jul;
61(14):5486-90.
PMID: 11454696
This report describes the isolation and partial purification of novel triterpenoid saponins [Fraction 35 (F035)] and two pure biologically active derivatives (termed avicins D and G) from Acacia victoriae, an...
3.
Haridas V, Higuchi M, Jayatilake G, Bailey D, Mujoo K, Blake M, et al.
Proc Natl Acad Sci U S A
. 2001 May;
98(10):5821-6.
PMID: 11344312
Anticancer agents target various subcellular components and trigger apoptosis in chemosensitive cells. We have recently reported the tumor cell growth inhibitory properties of a mixture of triterpenoid saponins obtained from...
4.
Mujoo K, Zhang L, Klostergaard J, Donato N
Int J Gynecol Cancer
. 2001 Mar;
10(2):105-114.
PMID: 11240661
Resistance to chemotherapy commonly compromises the treatment of many advanced cancers. Evidence suggests a correlation between chemoresistance and more aggressive tumor growth, possibly through accumulation of additional genetic defects in...
5.
Murray J, Kleinerman E, Jia S, Rosenblum M, Eton O, Buzaid A, et al.
J Immunother Emphasis Tumor Immunol
. 1996 May;
19(3):206-17.
PMID: 8811495
We performed a phase Ia/Ib trial of chimeric anti-GD2 monoclonal antibody 14.18 (ch14.18) in combination with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) to determine the maximum tolerated dose as well...
6.
Mujoo K, Maneval D, Anderson S, Gutterman J
Oncogene
. 1996 Apr;
12(8):1617-23.
PMID: 8622881
Mutations of p53 gene are reported in 50-60% of human cancers and reintroduction of wild-type p53 can suppress cell proliferation. In this study, replication deficient recombinant adenovirus encoding wild-type p53...
7.
Rosenblum M, Cheung L, Kim S, Mujoo K, Donato N, Murray J
Cancer Immunol Immunother
. 1996 Feb;
42(2):115-21.
PMID: 8620520
The development of cellular resistance to immunotoxins has been demonstrated in a variety of models and can involve a number of mechanisms. For the present study, an immunotoxin was utilized...
8.
Mujoo K, Cheung L, Murray J, Rosenblum M
Cancer Immunol Immunother
. 1995 May;
40(5):339-45.
PMID: 7600567
Antibody ZME-018 is directed against the gp240 glycoprotein on the surface of more than 80% of human melanoma cell lines and fresh biopsy specimens. Previous studies in our laboratory described...
9.
Rosenblum M, Cheung L, Mujoo K, Murray J
Cancer Immunol Immunother
. 1995 May;
40(5):322-8.
PMID: 7600565
The ability of monoclonal antibody conjugates to re-direct plant or bacterial toxins, chemotherapeutic agents and radionuclides to selected target cells has been well-documented. Recombinant human tumor necrosis factor (TNF) is...
10.
Murray J, Cunningham J, Brewer H, Mujoo K, Zukiwski A, Podoloff D, et al.
J Clin Oncol
. 1994 Jan;
12(1):184-93.
PMID: 8270976
Purpose: The purpose of this phase I trial was to determine the toxicity and maximum-tolerated dose (MTD) of murine monoclonal antibody (Mab) 14G2a (anti-GD2) in cancer patients. Patients And Methods:...